Friday, March 14, 2025 3/14/2025

Development of a mucosal, polyanhydride-based nanoparticle vaccine for use against RSV infection in the neonate

Award Number: R01HD095880
ORGANIZATION: NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Abstract

Project Summary/Abstract Respiratory syncytial virus (RSV) is a leading cause of severe acute lower respiratory tract infection in infants and children worldwide. Bovine RSV (BRSV) is closely related to human RSV and a significant cause of morbidity in young cattle. BRSV infection in calves displays many striking similarities to HRSV infection in humans, and cattle are an outbred population that is naturally susceptible to BRSV infection. Therefore, BRSV infection in calves represents an excellent model for studying RSV infection and antiviral immunity in children. RSV is poorly immunogenic and this has been a complicating factor in the development of a safe and effective RSV vaccine. Polyanhydride nanovaccines have shown great promise as adjuvants and vaccine delivery vehicles in rodent models due to their ability to promote enhanced immunogenicity through both the route of administration and the ability to provide sustained antigen exposure. In a previously funded NIH grant, the polyanhydride nanovaccine platform was used to develop an efficacious, mucosal nanovaccine that incorporated the post-fusion F and G proteins from BRSV. Neonatal calves vaccinated with the BRSV-F/G nanovaccine develop virus-specific cellular and humoral immune responses in the mucosa, and demonstrate significant reductions in viral burden and disease-associated pathology. The overall objective of this application is to improve upon the established efficacy of the polyanhydride nanoparticle platform for use against RSV infection in the neonate, and to further characterize the mucosal immune responses that correlate with resistance to RSV infection. The experiments in Aim 1 build upon the established efficacy of the post-fusion F/G nanovaccine with the incorporation of additional toll like receptor agonists and modifications to the mucosal/parenteral inoculation regimen. The experiments in Aim 2 will determine the efficacy of a mucosal nanovaccine that incorporates the pre-fusion F and G proteins from BRSV, as well as characterize the antibody response towards the pre-fusion and post-fusion F protein in the respiratory tract of neonatal calves. The experiments in Aim 3 will determine the duration of immunity induced by polyanhydride nanoparticle vaccination, while determining the mucosal immune responses that correlate with long-term resistance to RSV infection in the calf. Much of our knowledge of RSV infection and immunity stems from studies in rodents and adult animals;; however, the experiments proposed here will study a natural host-pathogen interaction and will examine the response in the neonate, the same population commonly affected by severe RSV disease. We anticipate that these studies will have a positive impact by identifying a safe and efficacious vaccine for use in children and animals, and by determining the immune responses that are necessary for long-term resistance against RSV infection in the young.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = -$22,710 )
2025	2022	IOWA STATE UNIVERSITY OF SCIENCE AND TECHNOLOGY	1350 BEARDSHEAR HALL	AMES	IA	50011	STORY	USA	Child Health and Human Development Extramural Research	000	4	1/3/2025	NON-COMPETING CONTINUATION	-$22,710
														Subtotal = -$22,710

Issue Date FY: 2022 ( Subtotal = $528,103 )
2022	2022	IOWA STATE UNIVERSITY OF SCIENCE AND TECHNOLOGY	515 MORRILL RD, 1350 BEARDSHEAR HALL	AMES	IA	50011	STORY	USA	Child Health and Human Development Extramural Research	000	4	7/26/2022	NON-COMPETING CONTINUATION	$528,103
														Subtotal = $528,103

Issue Date FY: 2021 ( Subtotal = $575,637 )
2021	2021	IOWA STATE UNIVERSITY OF SCIENCE AND TECHNOLOGY	515 MORRILL RD, 1350 BEARDSHEAR HALL	AMES	IA	50011	STORY	USA	Child Health and Human Development Extramural Research	000	3	8/2/2021	NON-COMPETING CONTINUATION	$575,637
														Subtotal = $575,637

Issue Date FY: 2020 ( Subtotal = $437,042 )
2020	2020	IOWA STATE UNIVERSITY OF SCIENCE AND TECHNOLOGY	515 MORRILL RD, 1350 BEARDSHEAR HALL	AMES	IA	50011	STORY	USA	Child Health and Human Development Extramural Research	000	2	7/11/2020	NON-COMPETING CONTINUATION	$437,042
														Subtotal = $437,042

Issue Date FY: 2019 ( Subtotal = $536,591 )
2019	2019	IOWA STATE UNIVERSITY OF SCIENCE AND TECHNOLOGY	515 MORRILL RD, 1350 BEARDSHEAR HALL	AMES	IA	50011	STORY	USA	Child Health and Human Development Extramural Research	001	1	9/17/2019	NEW	-$5,096
2019	2019	IOWA STATE UNIVERSITY OF SCIENCE AND TECHNOLOGY	515 MORRILL RD, 1350 BEARDSHEAR HALL	AMES	IA	50011	STORY	USA	Child Health and Human Development Extramural Research	000	1	9/11/2019	NEW	$541,687
														Subtotal = $536,591

Grand Total All Awards = $2,054,663

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of a mucosal, polyanhydride-based nanoparticle vaccine for use against RSV infection in the neonate

Award Number: R01HD095880

ORGANIZATION: NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer